AGE-RELATED MACULAR DEGENERATION (AMD)

This study is testing how well a higher dose (8mg) of the drug Aflibercept, also known as Eylea, works in the first two months for people with wet age-related macular degeneration (AMD). Researchers will measure changes in retinal fluid and vision in 50 participants. The goal is …

This study tests a small telescope-like implant called SING IMT™ for people with advanced age-related macular degeneration (AMD) who have poor central vision in both eyes. The device is placed inside the eye during surgery, either replacing or sitting in front of the existing len…

This study tests whether a 6-month online stationary cycling program can improve vision, physical function, and thinking skills in veterans aged 65-89 with intermediate age-related macular degeneration (AMD). Researchers will measure contrast sensitivity, night vision, and visual…

This phase 3 trial tests two injectable drugs, pozelimab and cemdisiran, alone or together, to slow the growth of geographic atrophy—an advanced form of dry age-related macular degeneration that causes central vision loss. About 975 participants will receive either the drugs or a…

This study tests an experimental drug called ONL1204, given as an eye injection, to see if it can slow the growth of blind spots in people with geographic atrophy, an advanced form of dry age-related macular degeneration. About 324 adults aged 55 and older will receive either the…

This study tests whether an oral drug called dimethyl fumarate (Tecfidera) can safely slow the growth of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 90 adults aged 55–85 with geographic atrophy will take the drug for 12 m…

This study tests whether an AI tool (VeriSee) can help doctors detect two common causes of vision loss—diabetic retinopathy and age-related macular degeneration—earlier than standard exams. About 4,300 adults with diabetes or aged 50+ will be randomly assigned to AI-assisted scre…

This study looks at three drugs (bevacizumab, ranibizumab, and aflibercept) used to treat age-related macular degeneration (AMD), a leading cause of blindness in older adults. Researchers will analyze costs and quality of life for 600 patients in France to see which treatment off…

This study collects fluid and blood samples from 260 people with age-related macular degeneration, diabetic retinopathy, or retinal detachment, plus healthy controls. Researchers will analyze proteins in these samples to identify markers that could help diagnose or track these ey…

This study is testing new ways to measure how well the eye adapts to darkness in people with early age-related macular degeneration (AMD) and in healthy volunteers. The goal is to find reliable tests that can be used in future treatment studies. Researchers will track changes ove…